Aarey Drugs & Pharmaceuticals Ltd. (BSE: 524412) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹324 Cr, it ranks #2,283 by market cap among the 6,197 Indian listed companies on FinBizNet, and #53 of 86 in Medicinal Chemicals and Botanical Products. At ₹115.75 (as of 16 Nov 2026), the share price is 0.2% below its 52-week high of ₹116.00 and 130.1% above its 52-week low of ₹50.31. The share price is up 16.0% over one year and up 36.3% over three months.
| Current Price | ₹115.75 |
|---|---|
| Market Cap | ₹324 Cr |
| BSE Code | 524412 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 82 |
| Return on Equity | 2.75% |
| Return on Assets | 1.23% |
| 52-Week Range | ₹50.31 – ₹116.00 |
| 1-Year Price Change | +16.0% |
| 3-Month Price Change | +36.3% |
| Beta (1Y) | 0.82 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.aareydrugs.com |
| Revenue | ₹89 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 1.5% |
| EPS (Basic) | ₹0.43 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Aarey Drugs & Pharmaceuticals Ltd. reported revenue of ₹89 Cr in Q2 FY27, up 5.3% from ₹84 Cr in Q2 FY26 and up 98.6% from ₹45 Cr in Q1 FY27. It posted a net profit of ₹1 Cr for the quarter, against a net profit of ₹1 Cr in Q2 FY26 (up 34.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹45 Cr (Q1 FY27) to ₹189 Cr (Q4 FY26). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹89 Cr | ₹1 Cr | 1.5% |
| Q1 FY27 | ₹45 Cr | ₹1 Cr | 2.3% |
| Q4 FY26 | ₹189 Cr | ₹2 Cr | 0.8% |
| Q3 FY26 | ₹96 Cr | ₹1 Cr | 0.6% |
| Q2 FY26 | ₹84 Cr | ₹1 Cr | 1.2% |
| Q1 FY26 | ₹102 Cr | ₹1 Cr | 1.3% |
| Q4 FY25 | ₹108 Cr | ₹0 Cr | 0.4% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 41.45% of Aarey Drugs & Pharmaceuticals Ltd.'s shares as of Sept 2026, against 39.06% in Dec 2025 (+2.39 percentage points). Delivery averaged 66.9% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company offers intermediates, including mono methyl urea, di methyl urea, ortho para nitro anisole, 2-bromomethyl-1,3-dioxolane, and uracil. It also provides active pharmaceutical ingredients, such as metformin HCl, mefenamic acid, and doxofylline. In addition, the company trades chemicals and solvents, including aromatic chemicals, chemical acids, chlor-alkali, glycols and glycol ethers, fiber intermediates, and acetates and esters, as well as industrial alcohols, ketones, amines, oleochemicals, intermediates, olefins, phosphates, fertilizers, monomers, and chemicals. It serves pharmaceutical formulation manufacturers and pharmaceutical merchant exporters. Aarey Drugs & Pharmaceuticals Limited was incorporated in 1990 and is headquartered in Mumbai, India.
1. Trading and Manufacturing Activities-This segment engages in the manufacture and supply of pharmaceutical raw materials, chemicals, pharmaceuticals ingredients, food colours, and flavours.
1. Trading and Manufacturing Activities-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Aarey Drugs & Pharmaceuticals Ltd. | ₹324 Cr | 82 | 2.75% | ₹89 Cr | +16.0% |
Listed by market capitalisation. Ratios are shown for context only.
Aarey Drugs & Pharmaceuticals Ltd. is trading at ₹115.75, with a market capitalisation of ₹324 Cr.
Aarey Drugs & Pharmaceuticals Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Aarey Drugs & Pharmaceuticals Ltd. has a P/E of 82 and a return on equity of 2.75%.
Aarey Drugs & Pharmaceuticals Ltd. is listed on the BSE under the scrip code 524412.
Aarey Drugs & Pharmaceuticals Ltd.'s share price is up 16.0% over one year and up 36.3% over three months. Its 52-week range is ₹50.31 to ₹116.00.
In Q2 FY27, Aarey Drugs & Pharmaceuticals Ltd. reported revenue of ₹89 Cr and net profit of ₹1 Cr, with basic EPS of ₹0.43 (standalone, parsed from the company's exchange filing).
Aarey Drugs & Pharmaceuticals Ltd. reported revenue of ₹89 Cr in Q2 FY27, up 5.3% from ₹84 Cr in Q2 FY26 and up 98.6% from ₹45 Cr in Q1 FY27.
Promoters held 41.45% of Aarey Drugs & Pharmaceuticals Ltd.'s shares as of Sept 2026, against 39.06% in Dec 2025 (+2.39 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.